Erythroid Progenitor Production via Hypoxic MSC Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating erythroid progenitor cells are limited by scalability and ineffective in producing ample amounts of starting cells for erythropoiesis, particularly in treating anemia caused by intrinsic or extrinsic red blood cell abnormalities.

Innovation Solution

The development of compositions and methods involving in vitro-activated bone marrow mesenchymal stem cells cultured under hypoxic conditions, combined with embryoid bodies or pluripotent stem cells, and erythropoietin to stimulate erythroid lineage commitment, mimicking the body's natural processes for red blood cell production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional methods are used to generate erythroid progenitor cells, then the process is simple, but scalability is limited and ample production is not achieved

Engineering Contradiction:

Improveproduction amount of erythroid progenitor cellsVSAvoidmethodology complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The invention segments the complex process of erythropoiesis into distinct stages: (1) generating pluripotent stem cells, (2) differentiating them into erythroid progenitors, and (3) maturing them into red blood cells. This segmentation allows each stage to be optimized independently, achieving scalable production while maintaining biological fidelity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention employs parameter changes in culture conditions, including hypoxic atmosphere (5-15% O2), specific growth factors (EPO, SCF, TPO, FLT3 ligand), and staged differentiation protocols. These controlled parameter changes enable high-yield production of erythroid progenitors while maintaining cell viability and functional integrity.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If bone marrow and cord blood hematopoietic stem cells are used, then erythroid progenitor production is attempted, but useable production has not been achieved

Engineering Contradiction:

Improveuseable production of erythroid progenitorsVSAvoidconsistency of erythroid progenitor generation

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The invention utilizes the self-organizing capacity of pluripotent stem cells to spontaneously differentiate into erythroid lineages when exposed to appropriate microenvironmental cues. This self-service mechanism eliminates the need for complex external steering, improving both productivity and reliability of erythroid progenitor generation.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The invention introduces intermediary substances including erythropoietin (EPO), stem cell factor (SCF), thrombopoietin (TPO), and FLT3 ligand as mediators that guide and enhance the differentiation process. These intermediaries act as chemical messengers that reliably trigger and sustain erythroid lineage commitment, ensuring consistent production.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If terminal differentiation and enucleation of erythroid progenitors is used, then red blood cell production is achieved, but production of ample starting cells has not been successful

Engineering Contradiction:

Improveamount of starting cells for erythropoiesisVSAvoidscalability of cell production

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The invention performs preliminary actions by first generating and expanding pluripotent stem cells in vitro before initiating the differentiation pathway toward erythroid lineages. This preliminary expansion step creates a robust starting population that can be reliably differentiated into ample amounts of erythroid progenitors, enabling scalable production.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention maintains continuity of useful action through sustained culture conditions that continuously support both self-renewal and differentiation. By keeping pluripotent stem cells in a state of active proliferation and controlled differentiation under hypoxic conditions with growth factors, the system continuously produces erythroid progenitors without interruption, ensuring ample and scalable output.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively generates enhanced numbers of erythroid progenitor cells, ameliorates anemia, and stimulates erythropoiesis, enabling scalable red blood cell production and erythropoietin synthesis.

Implementation Method 1

culturing the cell of (a) under hypoxic conditions for at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 or more hours

Methodology Applied

Scientific EffectHypoxia:

Data Source

PatentUS8703487B2Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells

Publication Date: 2014.04.22 RGT UNIV OF CALIFORNIA

AI summary

The invention provides compositions for making erythroid progenitor cells that comprise in vitro-activated bone marrow mesenchymal stem cells and embryoid bodies (EBs) or pluripotent stem cells, and methods for making and using them, including ameliorating (e.g., preventing or treating) anemia and/or stimulating erythropoiesis. In one embodiment, the invention provides methods of increasing propensity of committed stem cell differentiation towards the erythroid lineage.